an update on the gimema lal2317 trial: sequential chemotherapy blinatumomab for ph-like all
Published 1 year ago • 105 plays • Length 1:39Download video MP4
Download video MP3
Similar videos
-
1:54
final results of the gimema lal2317 trial: sequential chemotherapy blinatumomab for ph- b-all
-
1:59
final analysis of the gimema lal2116 (d-alba) trial: dasatinib blinatumomab in ph b-all
-
0:22
blinatumomab plus ponatinib for all update coming soon at eha 2021
-
2:32
blinatumomab and ponatinib in newly diagnosed ph all: updates from a phase ii trial
-
2:13
an update on the management of ph all
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
3:54
a case study from the ecog-e1910 trial: early blinatumomab treatment in all
-
2:11
update on phase i/ii study of azacitidine, venetoclax and gilteritinib in patients with flt3 aml
-
9:02
dasatinib-blinatumomab for adult ph all
-
1:09
menin inhibitors for the treatment of aml: insights into the covalent-101 trial
-
1:52
aml19 update: improvement in os in patients with npm1-mutated aml treated with flag-ida-go
-
9:44
an update on the quantum-first trial: quizartinib plus chemotherapy in flt3-mutated aml
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
1:29
the current landscape of immunotherapy for aml: an update from ash 2023
-
2:14
update on the aml treatment landscape
-
2:26
impact of allelic state on os in tp53-mutant aml and hr-mds
-
2:04
preliminary results from the blin01 trial
-
0:44
predictors of poor response to azacitidine, venetoclax, and magrolimab in tp53-mutated aml
-
3:07
how age as a prognostic factor affects treatment options for all